Organization (Industry)
Medtronic, Inc.
ClinicalTrials.gov lists Medtronic, Inc. as lead sponsor of 42 trials. It has 1 active development program.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 30 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 31 in 2026 and about 23 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Medtronic, Inc.: 42 lead-sponsored trials and 20 legal-entity registrations. The parent company on record for Medtronic, Inc. is MEDTRONIC PUBLIC LIMITED COMPANY, which does not have its own page on this site.
Disease areas (283)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Heart Failure | 92 |
| Atrial Fibrillation | 66 |
| Diabetes Mellitus | 56 |
| Coronary Disease | 33 |
| Diabetes Mellitus, Type 1 | 33 |
Showing 5 of 283 disease areas.
Trials by start year as sponsor or collaborator (29)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 30 |
| 2025 | 16 |
| 2024 | 13 |
| 2023 | 28 |
| 2022 | 19 |
| 2021 | 32 |
| 2020 | 36 |
| 2019 | 32 |
| 2018 | 31 |
| 2017 | 47 |
Showing 10 of 29 years.
Recruitment duration, a model prediction: none of the 42 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Observational | Heart Failure | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 69% hit target (n=16) | 58% on time (n=19) |
Journals published in (409)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 73 |
| Circulation | 70 |
| Journal of the American College of Cardiology | 54 |
| European heart journal | 39 |
| Anesthesiology | 27 |
Showing 5 of 409 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 8,877 | 1,164 | 2025-12-30 |
SEC-reported annual financials (12)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2026 | 36,364,000,000 | 4,801,000,000 | 2,873,000,000 |
| 2025 | 33,537,000,000 | 4,662,000,000 | 2,732,000,000 |
| 2024 | 32,364,000,000 | 3,676,000,000 | 2,735,000,000 |
| 2023 | 31,227,000,000 | 3,758,000,000 | 2,696,000,000 |
| 2022 | 31,686,000,000 | 5,039,000,000 | 2,746,000,000 |
| 2021 | 30,117,000,000 | 3,606,000,000 | 2,493,000,000 |
| 2020 | 28,913,000,000 | 4,789,000,000 | 2,331,000,000 |
| 2019 | 30,557,000,000 | 4,631,000,000 | 2,330,000,000 |
| 2018 | 29,953,000,000 | 3,104,000,000 | 2,256,000,000 |
| 2017 | 29,710,000,000 | 4,028,000,000 | 2,193,000,000 |
Showing 10 of 12 fiscal years.
Financing and grant events (28)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-03-18 | Other financing | not disclosed | Sec extracted |
| 2026-03-09 | Debt financing | not disclosed | Edgar offerings |
| 2026-03-09 | Other financing | not disclosed | Sec extracted |
| 2025-09-29 | Debt financing | not disclosed | Sec extracted |
| 2025-09-29 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 28 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| FY2025 | 2045 |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2026 | not disclosed | not disclosed |
Organization relationships (186)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 14 |
| State University System of Florida | Co sponsors trial with | 9 |
| Stanford University | Co sponsors trial with | 8 |
| Johns Hopkins University | Co sponsors trial with | 4 |
| Sheba Medical Center | Co sponsors trial with | 4 |
Showing 5 of 186 relationships.
Latest dated events (9,575)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 9,575 events.
Biomarker capability evidence (428)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial collaborator | Named in trial inclusion criteria |
| ACSBG1 | Trial collaborator | Named in trial inclusion criteria |
| ACSM1 | Trial collaborator | Named in trial inclusion criteria |
| AFF1 | Trial collaborator | Named in trial inclusion criteria |
| AGT | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 428 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.